Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Combined Effects of Drugs: Antagonism01:30

Combined Effects of Drugs: Antagonism

The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Flow cytometric evaluation of monoclonal antibodies for cross-reactivity with feline leukocytes.

Frontiers in veterinary science·2026
Same author

Computed tomography can assess aortic valve stenosis by planimetry, enhances the continuity equation, reveals an anatomical ratio that mimics the dimensionless velocity index and demonstrates limitations in the use of calcification in stenosis severity assessment.

Clinical radiology·2026
Same author

Pain perception during baroreceptor unloading by lower body negative pressure.

European journal of pain (London, England)·2024
Same author

CT pulmonary angiography: optimising acute thoracic imaging by fixed-timing contrast medium delivery with a modified breathing instruction.

Clinical radiology·2023
Same author

Wind-borne dispersion of <i>Echinococcus multilocularis</i> eggs - a flight model.

Journal of helminthology·2022
Same author

A quality-improvement project to enhance systemic arterial contrast opacification in CT for trans-catheter aortic valve implantation.

Clinical radiology·2022

Related Experiment Video

Updated: Jun 2, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Small molecule TSHR agonists and antagonists.

S Neumann1, M C Gershengorn

  • 1National Institutes of Health, NIDDK, CEB, Receptor and Hormone Action Section, MD 20892, Bethesda, USA. susannen@intra.niddk.nih.gov

Annales D'Endocrinologie
|April 23, 2011
PubMed
Summary

Researchers developed small molecule agonists and antagonists for the TSH receptor (TSHR). These compounds show potential for diagnosing thyroid cancer and treating Graves' disease, offering easier administration than current treatments.

More Related Videos

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Related Experiment Videos

Last Updated: Jun 2, 2026

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Quantifying Agonist Activity at G Protein-coupled Receptors
11:45

Quantifying Agonist Activity at G Protein-coupled Receptors

Published on: December 26, 2011

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
10:51

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Area of Science:

  • Endocrinology
  • Pharmacology
  • Molecular Biology

Background:

  • The TSH receptor (TSHR) is crucial for thyroid hormone regulation and implicated in thyroid diseases.
  • Current treatments like recombinant human TSH (rhTSH) have limitations, including production challenges and injection administration.
  • Developing small molecule ligands for TSHR offers a promising therapeutic and diagnostic avenue.

Purpose of the Study:

  • To develop and characterize small molecule agonists and antagonists for the TSHR.
  • To evaluate the in vivo efficacy of a TSHR agonist for potential clinical applications.
  • To identify novel antagonists for inhibiting TSHR signaling in conditions like Graves' disease.

Main Methods:

  • Synthesis and screening of small molecule ligands targeting TSHR.
  • In vivo studies in mice to assess oral bioavailability and efficacy of TSHR agonists.
  • In vitro assays using primary human thyrocytes to test TSHR antagonists against TSH and TSAb stimulation.

Main Results:

  • A novel small molecule TSHR full agonist was developed, demonstrating oral bioavailability and efficacy in elevating thyroxine and thyroidal radioiodide uptake in mice.
  • The first small molecule TSHR antagonists were identified, effectively inhibiting TSH- and TSAb-stimulated signaling in human thyrocytes.
  • These findings provide proof-of-concept for small molecule TSHR modulators.

Conclusions:

  • Small molecule agonists and antagonists targeting the TSHR are feasible.
  • These ligands represent lead compounds for developing improved diagnostics and therapeutics for thyroid disorders.
  • Further development could lead to orally administered treatments for thyroid cancer follow-up and Graves' disease.